Clinical Trials Logo

Hyperparathyroidism clinical trials

View clinical trials related to Hyperparathyroidism.

Filter by:

NCT ID: NCT00189501 Completed - Nephrology Clinical Trials

A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)

Start date: December 2004
Phase: N/A
Study type: Observational

Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters

NCT ID: NCT00175149 Terminated - Clinical trials for Chronic Kidney Disease

Active Vitamin D Effect on Left Ventricular Hypertrophy

Start date: January 2002
Phase: Phase 4
Study type: Interventional

Left ventricular hypertrophy (LVH) predicts mortality at start of dialysis. Prevention of of LVH is important. It is not known whether secondary hyperparathyroidism might induce LVH. In the present study patients are randomised to 1.25 dihydroxycholecalciferol or no treatment to study the effect on LVH.

NCT ID: NCT00169806 Recruiting - Hyperparathyroidism Clinical Trials

Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis

Start date: November 1998
Phase: N/A
Study type: Interventional

Kidney stones are very common. They affect 3-5% of the population in the United States. Many people are hospitalized for the treatment of kidney stones and some may die. Better understanding of what causes kidney stones is useful in both the treatment and prevention of kidney stones. However, exactly what causes kidney stones is unknown. The most common type of kidney stones contains calcium, which sometimes is attached to a part of the kidney important in producing the final urine, called the papilla. The investigators have noticed that persons who form kidney stones seem to have more papilla with stones attached. They propose to study these areas of the papilla, called Randall's plaques (named after their discoverer), in patients undergoing surgery for kidney stones.

NCT ID: NCT00135304 Completed - Clinical trials for Secondary Hyperparathyroidism

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

Start date: August 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) secondary hyperparathyroidism (HPT) treatment targets for both biointact parathyroid hormone (biPTH) and calcium-phosphorus (Ca x P) product.

NCT ID: NCT00132431 Completed - Clinical trials for Chronic Kidney Disease

START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism

Start date: July 2004
Phase: Phase 4
Study type: Interventional

The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with dialysis and have uncontrolled secondary hyperparathyroidism (HPT).

NCT ID: NCT00123461 Completed - Renal Failure Clinical Trials

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Start date: July 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to demonstrate the safety and effectiveness of Hectorol® (doxercalciferol) capsules in treating patients with Stage 3 or Stage 4 chronic kidney disease (CKD) with secondary hyperparathyroidism who have vitamin D levels in the normal range. Previous studies with doxercalciferol were conducted in patients who had low levels of vitamin D.

NCT ID: NCT00117052 Completed - Clinical trials for End Stage Renal Disease

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.

NCT ID: NCT00110929 Completed - Clinical trials for End Stage Renal Disease

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

Start date: November 2002
Phase: Phase 2
Study type: Interventional

The purpose of this research is to study the efficacy and safety of AMG 073 in patients with kidney failure who are being treated with hemodialysis or peritoneal dialysis and who also have secondary hyperparathyroidism (HPT).

NCT ID: NCT00094484 Completed - Clinical trials for Chronic Kidney Disease

Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).

NCT ID: NCT00073710 Completed - Clinical trials for Chronic Kidney Disease

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

Start date: September 2004
Phase: Phase 4
Study type: Interventional

A study to investigate the effects of Zemplar and Calcijex on intestinal calcium absorption in hemodialysis subjects.